Rab13 and Net1 ASOs for Selective Peripheral Translation Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a discordance between Rab13 RNA and protein distributions, with Rab13 RNA being enriched in the periphery while the protein assumes a perinuclear distribution, which affects cell migration in cancer cells, and existing methods fail to specifically target peripheral Rab13 translation without affecting overall protein distribution or localization.
Innovation Solution
Development of Rab13 and Net1 antisense oligonucleotides (ASOs) that are specific for a GA-rich motif, reducing peripheral translation of Rab13 and Net1 RNAs by at least 20% to 100%, using chemical modifications such as phosphorothioate and 2′-fluoro, and potentially attaching them to nanoparticles for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to target Rab13, then overall protein distribution is affected, but peripheral translation cannot be specifically inhibited
Solution Approach 1:
The patent applies local quality by designing ASOs that specifically target the GA-rich motif in the Rab13 3'UTR, which is enriched at peripheral protrusions. This allows selective inhibition of translation at peripheral locations while leaving perinuclear translation unaffected, thereby achieving spatially selective protein expression without disrupting overall protein distribution
Solution Approach 2:
The invention segments the translation process into spatially distinct zones by using ASOs to specifically block translation at peripheral protrusions. The GA-rich motif serves as a segmentation marker that allows differential regulation of translation in peripheral versus perinuclear regions, enabling independent control of local protein synthesis
2Productivity
If peripheral Rab13 translation is inhibited, then cell migration is reduced, but overall protein levels may be affected
Solution Approach 1:
The ASO therapy applies local quality by specifically targeting peripheral translation sites where the GA-rich motif is enriched. This selectively reduces Rab13 protein synthesis at the cell periphery (affecting migration) while preserving protein synthesis in the perinuclear region, thereby maintaining overall protein concentrations while selectively impairing migratory function
3Manufacturing precision
If ASOs are used to target Rab13, then peripheral translation is reduced, but delivery efficiency to specific cellular locations must be optimized
Solution Approach 1:
The patent employs delivery vehicles such as lipid nanoparticles or conjugation to cell-penetrating peptides as intermediaries to transport ASOs into cells. These mediators facilitate efficient cellular uptake and intracellular release of ASOs, enabling effective targeting of peripheral Rab13 translation without requiring complex direct delivery methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ASOs effectively reduce peripheral translation of Rab13 and Net1 RNAs, inhibiting cell migration and metastasis in various cancer types, including breast, lung, colon, pancreas, ovary, uterus, cervix, skin, prostate, bone, central nervous system, and head and neck cancers, with potential synergistic effects when combined with anti-cancer therapies.
Implementation Method 1
Rab13 and Net1 antisense oligonucleotides (ASOs), which are specific for a GA-rich motif having the consensus sequence RGAAGRR
Data Source
AI summary
Provided herein are antisense oligonucleotides (ASOs) specific for Rab13 and Net1, for example specific for a GA-rich region of the 3′-UTR. In some examples, the ASOs are modified. Methods of using these ASOs to reduce the migration of metastatic cancer cells are provided, for example as a use to treat metastatic cancer.